Astellas Venture Management LLC

	Country	Date	Notes
Mission Bay Capital III		16 Sep 2019	Fund Closing Active
Cleave Biosciences Inc Drug development company focused on novel targets in cellular protein homeostasis pathways	United States	1 Oct 2011	Series A Active
Fate Therapeutics Inc	United States	1 Nov 2009	Series B Initial investment. Round participant. Active
Nereus Pharmaceuticals Inc	United States	1 Aug 2007	Series D
Lectus Therapeutics Ltd	United Kingdom		N/A
Linden Bioscience Inc	United States		N/A
Memory Pharmaceuticals Corp	United States		N/A
IRX Therapeutics Inc	United States		N/A
Neuronautics Inc	United States		N/A
Cytomyx Holdings PLC	United Kingdom		N/A
Ception Therapeutics Inc Ception Therapeutics, Inc. is an emerging biopharmaceutical company.	United States		N/A Active
Viamet Pharmaceuticals Inc	United States		N/A
PhysioGenix Inc	United States		N/A
Prolysis Ltd	United Kingdom		N/A
DecImmune Therapeutics Inc Developer of antibodies to reduce tissue damage and improve ventricular function associated with myocardial infarction	United States		N/A
Cellzome AG A drug discovery and development company and a leader in the use of chemical proteomics technologies.	Germany		N/A Active
Renovar Inc	United States		N/A
Adhelex Technologies	Canada		N/A Active
Epizyme Inc Focusing on the discovery and development of innovative drugs targeting epigenetic enzymes, in particular histone methyltransferases (HMTs).	United States		N/A
Evolva Holding SA	Switzerland		N/A